Catalent, Inc. is a holding company ... Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing ...
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
Fintel on MSN1mon
Baird Downgrades Catalent (CTLT)Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring ...
Reuters on MSN22d
Consumer groups ask FTC to block Novo Holdings-Catalent dealA Catalent spokesperson reiterated the ... but said that the drugmaker has secured near-term supplies for its clinical trials ...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...
“These efforts are critical to ensure a consistent and high-quality supply of NUZ-001 for both clinical trials and future ...
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback